Clinical trials
Not yet recruiting Leukemia, Myelogenous, Chronic, BCR-ABL Positive trials
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
20 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2022 | 2 |
| 2024 | 2 |
| 2025 | 2 |
| 2026 | 12 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Not yet recruiting | 20 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Assiut University | 3 |
| Gruppo Italiano Malattie EMatologiche dell'Adulto | 2 |
| Jiangsu Hansoh Pharmaceutical Co., Ltd. | 2 |
| Novartis Pharmaceuticals | 2 |
| Carmen Fava | 1 |
| Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | 1 |
| Fred Hutchinson Cancer Center | 1 |
| Guangdong Provincial People's Hospital | 1 |
| Ossium Health, Inc. | 1 |
| Prof. Dr. med. Andreas Hochhaus | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 20 |
| Leukemia, Myeloid, Acute | 5 |
| Leukemia, Myeloid, Chronic-Phase | 5 |
| Leukemia, Biphenotypic, Acute | 3 |
| Myelodysplastic Syndromes | 3 |
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 3 |
| Hematologic Neoplasms | 2 |
| Leukemia | 2 |
| Lymphoma, Non-Hodgkin | 2 |
| Anemia, Refractory, with Excess of Blasts | 1 |
Trials
Showing 51 to 20 of 20. Each trial links to its page on Pharma Observatory.
No trials match these filters.
Try a different keyword, or clear a filter.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.